Projects per year
Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Gary Kobinger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Pandemic Preparedness: Biocontainment Facility upgrade and Integration at UTMB/Galveston National Laboratory
Kobinger, G. (PI)
National Institute of Allergy and Infectious Diseases
9/16/22 → 2/28/25
Project: Research project
-
EBOV002, a Phase 1b, Placebo-controlled, Single-center Randomized Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of INO-4201 as a Booster Vaccination in Healthy Volunteers Who Have Previously Received the VSV-ZEBOV Vaccine
Kobinger, G. (PI)
GuardRX ( Award #HR00112200052)
11/1/22 → 1/19/23
Project: Research project
-
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers
Kobinger, G. (PI)
9/15/22 → 11/17/22
Project: Research project
-
An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses
de La Vega, M. A., Xiii, A., Massey, S., Spengler, J. R., Kobinger, G. P. & Woolsey, C., 2024, In: Expert Opinion on Drug Discovery. 19, 10, p. 1185-1211 27 p.Research output: Contribution to journal › Review article › peer-review
Open Access1 Scopus citations -
Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp
Wong, G., Bienes, K. M., XIII, A., Fausther-Bovendo, H. & Kobinger, G. P., Jun 2024, In: Antiviral research. 226, 105873.Research output: Contribution to journal › Review article › peer-review
Open Access2 Scopus citations -
Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques
Berger, A., Pedersen, J., Kowatsch, M. M., Scholte, F., Lafrance, M. A., Azizi, H., Li, Y., Gomez, A., Wade, M., Fausther-Bovendo, H., de La Vega, M. A., Jelinski, J., Babuadze, G., Nepveu-Traversy, M. E., Lamarre, C., Racine, T., Kang, C. Y., Gaillet, B., Garnier, A. & Gilbert, R. & 5 others, , Mar 29 2024, In: Vaccines. 12, 4, 369.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Research and product development for Crimean–Congo haemorrhagic fever: priorities for 2024–30
Semper, A. E., Olver, J., Warner, J., Cehovin, A., Fay, P. C., Hart, P. J., Golding, J. P., Benassi, V., Preziosi, M. P., Al-Asadi, K. H. R., Blumberg, L. H., de la Fuente, J., Elaldi, N., Fletcher, T., Formenty, P. B. H., Gouya, M. M., Günther, S., Hewson, R., Jamil, B. & Kobinger, G. & 10 others, , 2024, (Accepted/In press) In: The Lancet Infectious Diseases.Research output: Contribution to journal › Review article › peer-review
1 Scopus citations -
UV-Inactivated rVSV-M2e-Based Influenza Vaccine Protected against the H1N1 Influenza Challenge
Olukitibi, T. A., Ao, Z., Azizi, H., Ouyang, M. J., Omole, T., McKinnon, L., Kobasa, D., Coombs, K., Kobinger, G. & Yao, X., May 20 2024, In: Frontiers in Bioscience - Landmark. 29, 5, p. 195 fbl2905195.Research output: Contribution to journal › Article › peer-review
1 Scopus citations